Idorsia thanks Guy Braunstein for his years of service as he retires Guy
Braunstein, currently Chief Medical Officer and member of the Idorsia Executive
Committee, to retire at the end of March 2024
Allschwil, Switzerland – March 22, 2024
Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as
Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development
and member of the Idorsia Executive Committee since the creation of Idorsia
will retire at the end of March 2024. Guy will continue to support Idorsia as
an advisor, especially in the analysis and interpretation of the data coming
from the programs that he has initiated and led during his time with the
company.
Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented:
“Over the last 15 years, Guy has made a huge contribution to Idorsia and to
Actelion before that. As Head of Global Clinical Development until 2022, Guy
was instrumental in successfully steering several drugs in several very
different indications from rare diseases and specialty indications, such as
pulmonary arterial hypertension, lysosomal disorders, and multiple sclerosis,
to public health issues including insomnia and hypertension, through to
approval. In his most recent role as Chief Medical Officer, Guy was critical in
unifying the company’s quality and governance standards to ensure an
uncompromisingly ethical and scientifically rigorous approach along the
lifecycle of all products in Idorsia’s pipeline. I am very happy that we can
continue to benefit from Guy’s vast experience after his retirement since he
will serve as an advisor to Idorsia.”
Guy Braunstein, MD, PhD, and Chief Medical Officer of Idorsia commented:
“It has been an absolute privilege to work with an outstanding team of experts
who are all dedicated to improving peoples’ lives with innovative medicines. I
believe that bringing new drugs to prescribers and having a real impact on
patients is one of the most rewarding endeavors. Having worked as a
pulmonologist practitioner for a number of years, and joined the pharmaceutical
industry in 1988, I am very proud of all that we have achieved over the past 15
years of my career at Actelion and Idorsia. I am satisfied that the clinical
development is in safe hands with Alberto Gimona and, with the support of
Antonio Olivieri, that we have all the correct checks and balances in place to
ensure appropriate and safe use of Idorsia’s medicinal products and medical
ethics in engagement with various stakeholders. I am therefore ready to hand
the reigns over and start my retirement. I am also very happy to stay involved
in the projects that have given me such job satisfaction over the years.”
The CMO role was created in 2022 to ensure that Idorsia’s approach to medical
governance and its policies and procedures are globally aligned and consistent
across Drug Discovery, Clinical Development, Pharmaceutical Development and
Global and Local Medical Affairs. From April 1 st , the CMO role will be
assumed by Antonio Olivieri, who will continue to lead the Global Medical
Affairs function of Idorsia, merging with Global Clinical Development reporting
into Alberto Gimona, Head of Global Clinical Development & Medical Affairs, and
member of the Idorsia Executive Committee.
Jean-Paul continued:
“I am very pleased that with Antonio, we already have the ideal candidate to
succeed Guy from within our ranks. Antonio joined Idorsia in 2020 and built our
Global Medical Affairs function from the ground up. In his new role as Chief
Medical Officer, Antonio will continue to ensure that we maintain our focus on
ethical excellence and communicating to the medical community about our
innovative portfolio.”
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
20-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe and North America –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 800 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF
